PLOS ONE · 10 authors, 9 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This preclinical study in pigs with induced exocrine pancreatic insufficiency validated an omega-3 substrate absorption challenge test. The test successfully differentiated the efficacy of different doses of a novel lipase, showing that two high doses were comparable to a standard porcine pancrelipase.
The study used an established surgical model of exocrine pancreatic insufficient (EPI) pigs to validate a novel omega-3 substrate absorption challenge test (SACT). Pigs were fed a high-fat diet and given a standardized omega-3 challenge, with plasma omega-3 and total fat levels measured over 24 hours. The results showed that administration of a novel microbially-derived lipase (SNSP003) at doses of 40, 80, and 120 mg significantly increased absorption of omega-3 fats by 51%, 89%, and 64%, respectively, compared to no lipase. The two highest SNSP003 doses (80 mg and 120 mg) demonstrated comparable efficacy to porcine pancrelipase, with no significant differences in plasma total fatty acid increases. The study concludes the omega-3 SACT can distinguish among lipase doses and correlates with global fat lipolysis, suggesting it may be a better indicator than the coefficient of fat absorption for future clinical research. Limitations include the use of a pig model, the small sample size, and the use of a DHA supplement containing ethyl esters.
